Human Genome Sciences (NASDAQ:HGSI)

CAPS Rating: 2 out of 5

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Recs

0
Player Avatar ryanman000 (91.35) Submitted: 9/19/2011 2:01:15 PM : Outperform Start Price: $12.54 HGSI Score: -2.22

Looking for $30 in 2 years

Featured Broker Partners


Advertisement